source
- Swiss biotech Windward Bio raises $165 million to launch Phase 3 asthma trial for China-derived drugSwiss biotech Windward Bio announced it has secured $165 million in financing. The capital will be used to move one of its two experimental medicines, originally discovered in China, into a Phase…
- AI drug repurposing in oncology hampered by fragmented data, curated knowledge neededAI tools are being used to look for new cancer indications for existing biologics, but the article notes that fragmented and disparate data sets limit even the most advanced models. Repurposing pr…